SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Andrew H who wrote (13778)1/26/1998 3:50:00 PM
From: Flagrante Delictu  Read Replies (1) | Respond to of 32384
 
Andy, Thanks for the tip on downloading Adobe Acrobat & viewing the update. I used the url provided by Howard S., so my thanks are also due to him. Lehman indicated LGND didn't lose much from PFE's cancellation of the phase 3 trials in metastatic breast cancer & encouragingly pointed out that PFE would now have more resources to expend on their trial of Droloxifene for the much larger indication of osteoporosis. In addition PFE mentioned they would try the compound in the prevention of breast cancer as well as other women's health issues. We were unaware of these possibilities previously & can now take some succor {iywpte} from them. Bernie {iywpte} = if you will pardon the expression.



To: Andrew H who wrote (13778)1/26/1998 9:02:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Andy, The wine is coming. It was much harder to find it than I expected, and I think I found the only store in Pittsburgh with more than one year. Wasn't sure which was better, so I have a 1994 and 1 1996. I thought that they could deliver, but only to residents of Pennsylvania, so I'm bring the two bottles in to a shipping company tomorrow. Sorry for the delay, but the website has kept me hopping and I guess I ahould have started my wine shopping earlier.



To: Andrew H who wrote (13778)1/26/1998 9:03:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Speaking of the website, the AHP/SBH merger has generated quite a bit of interest (over 8000 hits in the past week), and I expect more action this week. Here's an older article from the San Diego Union Tribune:

SmithKline, American Home discuss merger; would be
biggest ever

ASSOCIATED PRESS

21-Jan-1998 Wednesday

NEW YORK -- SmithKline Beecham PLC and rival drug maker American Home
Products Corp. said yesterday they are considering the biggest corporate
merger ever, sending stocks of other pharmaceutical companies higher as
Wall Street poised for another round of merger mania.

Investors speculated that if two of the world's biggest drug makers
combine, the deal would set off a repeat of the drug industry's 1996 frenzy
among drug makers.

"There will be another wave of consolidation," said Hemant K. Shah, an
independent drug industry analyst in Warren, N.J. "If this goes through,
some other companies will have to think. How do you compete?"

In separate statements, American Home and SmithKline Beecham said there are
no guarantees the talks will lead to a merger. The drug makers declined
further comment until the discussions are concluded.

It remains unclear how the deal would be structured, but analysts say the
combined company would likely be a merger of equals based somewhere in the
corridor that stretches from New York to Philadelphia.

At yesterday's stock price, American Home is worth about $58 billion. If
SmithKline, valued at more than $63 billion, were to buy American Home, the
deal would eclipse the most expensive merger announced to date, the planned
buyout of MCI Communications Corp. by WorldCom Inc. for stock valued at
about $37 billion.

The combined company would have sales of about $24 billion, giving it the
most health-care revenues of any company. Five other companies, including
Nestle, have more overall sales, but much of their revenue comes from
outside the health care business.

"On top of that they will become the leading consumer brand company in
over-the counter products," Goldman Sachs analyst Prem Lachman said.

A merger would also unite two companies divided by history and an ocean.
Madison, N.J.-based American Home -- whose vast product line includes
Robitussin cough medicines, Advil pain relievers and the nation's
most-prescribed drug, the estrogen compound Premarin -- is 82-years old.

Its drug-making division, Wyeth-Ayerst Laboratories, goes back to 1860,
when John Wyeth and his brother Frank established a drugstore in the unit's
current home of Philadelphia.

London-based SmithKline -- maker of the antidepressant Paxil and
over-the-counter products such as Aquafresh toothpaste, Geritol vitamins,
the Nicoderm anti-smoking patch and Tum's antacids -- was created in the
1989 merger of SmithKline Beckman Corp. and Britain's Beecham Group PLC.

Its roots go back to 1830, when John K. Smith opened his first drugstore in
Philadelphia, where the company keeps its U.S. headquarters.



To: Andrew H who wrote (13778)1/26/1998 9:14:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Andy, Here what the Washington Post had to say last week on the merger possibilities:

Big Drug Firms Considering
Combination

By David S. Hilzenrath
Washington Post Staff Writer
Wednesday, January 21, 1998; Page C11

SmithKline Beecham PLC and American Home Products
Corp. said yesterday that they are considering a merger, which
would create the nation's largest supplier of prescription drugs
and the global leader in over-the-counter remedies.

The negotiations show that the consolidation of market power
in the health care industry is still in high gear.

Though neither company has been an industry star from a
financial standpoint, analysts said, they could cut costs and
increase their market clout if they combined.

"Companies that are lagging will look to come together and
make one plus one equal three," said Edmund Debler, an
industry analyst at the research firm Mehta Partners LLC. "If
you can take a clean-slate approach . . . you could make
something very exciting."

SmithKline Beecham, based in England, markets brand names
such as Paxil for depression, Tagamet for heartburn and ulcers,
Nicoderm and Nicorette to help smokers quit, and other
drugstore items as diverse as Contac, Tums, Geritol, Phillips'
Milk of Magnesia, Sucrets, Binaca, Vivarin and Aquafresh.
SmithKline has invested heavily in research by a Rockville firm,
Human Genome Sciences Inc.

SmithKline had worldwide sales of $12.4 billion in 1996.

American Home Products, based in Madison, N.J., is the
company behind Premarin, Advil, Robitussin, Dimetapp, and
Centrum vitamins. It remains under a cloud of potential liability
from dexfenfluramine, sold as Redux, and fenfluramine, sold as
Pondimin, two diet drugs linked to medical problems in some
patients. Both were withdrawn from the market last year. AHP
posted revenue of $14.1 billion in 1996.

The two companies declined to discuss the negotiations in
detail, adding in brief statements released yesterday that
nothing may come of their talks.

Investors reacted with enthusiasm, boosting SmithKline's share
price by $2.56 1/4, to $59.56 1/4, and American Home's by
$13.56 1/4, to $94.25.

In the $93 billion U.S. market for prescription drugs, American
Home Products had sales of $5.4 billion and SmithKline had
sales of $4 billion during the 12-month period that ended Nov.
30, according to IMS America Ltd., a health care information
company. Combined, they would overtake Bristol-Myers
Squibb Co., which had the largest U.S. market share with sales
of $5.7 billion, according to IMS.

In terms of worldwide prescription drug sales, the combined
business would rank first or a close second to Novartis
Pharmaceuticals Corp., analyst Hemant K. Shah said.

The clearest advantage of merging is that the companies could
slash their overhead, eliminating jobs and closing redundant
facilities, analysts said. In addition, access to expanded
distribution channels around the world could help them recoup
the huge investments required to develop new drugs.

But fundamental changes in the health care industry in recent
years have given drug companies added incentive to
consolidate. One major impetus is the consolidation of buying
power among big purchasers of pharmaceuticals, such as
managed-care health plans and mail-order pharmacies.

Managed-care companies are "looking for a smaller number of
bigger companies to provide their prescription drug needs,"
said Steven B. Gerber, an analyst with the investment firm
CIBC Oppenheimer & Co.

The same holds for over-the-counter products, as suppliers vie
for precious shelf space in drugstore aisles.

"You want to be the mega producer of over-the-counter
products," said Peter Seaver, the former head of
pharmaceutical marketing for Upjohn Co. and now president
of Kaleidoscope Television, a cable network devoted to health
care.

Staff researcher Richard Drezen contributed to this report.

DRUG MERGER TALKS

SmithKline Beecham and its rival drug maker American Home
Products are considering a merger that would create the
world's biggest over-the-counter drug company.

SMITHKLINE BEECHAM

Business: Pharmaceuticals: researches and makes prescrip-tion
and over-the-counter drugs; world's biggest maker of vaccines;
also consumer health care, health care services

Products: Contac, Geritol, Tums, Tagamet

Headquarters: London (U.S. headquarters in Philadelphia)

Established: 1830 as a small Philadelphia apothecary

Employees: 53,000 worldwide

1996 revenue: $12.30 billion

1996 earnings: $1.74 billion

Ticker symbol: SBH (NYSE)

Web address: sb.com

AMERICAN HOME PRODUCTS

Business: Developer, manufacturer and marketer of
prescription and over-the-counter drugs; also agricultural
products, animal health care and medical devices; includes
food and household-products divisions

Products: Advil, Anacin, Centrum, Chap Stick

Based: Madison, N.J.

Established: 1926

Employees: 67,710

1996 revenue: $14.09 billion

1996 earnings: $1.88 billion

Ticker symbol: AHP (NYSE)

Web address: ahp.com

SOURCES: Company reports, Bloomberg News